Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 8, 2021
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On November 15, 2021, Dan Brennan, executive vice president and chief financial officer, and Lauren...
-
Oct 27, 2021
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and...
-
Oct 20, 2021Terms Include Patent License for Micro-Tech’s Continued Sales of Hemostasis Clips
October 20, 2021 – Boston Scientific Corporation announces that it reached a settlement with Micro-Tech Endoscopy resolving claims of patent infringement by Boston Scientific against Micro-Tech...
-
Oct 6, 2021Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement
Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at...
-
Oct 6, 2021Acquisition to add new left heart access platforms to electrophysiology and structural heart portfolios
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to...
-
Oct 5, 2021Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism
Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular...
-
Oct 5, 2021Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions
Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...
-
Oct 4, 2021
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2021 on Wednesday, October...
-
Sep 21, 2021Company to add mechanical thrombectomy platform to peripheral interventions portfolio
Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free...
-
Sep 20, 2021EPOCH trial represents the first positive phase 3 study for selective internal radiation therapy
Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints,...